Form 4: Acadia Pharmaceuticals EVP, CFO Mark C. Schneyer Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, reported the sale of 772 shares of common stock to cover withholding taxes related to the vesting of restricted stock units.
Summary
- Mark C. Schneyer, the EVP and CFO of Acadia Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports the sale of 772 shares of Acadia Pharmaceuticals common stock on February 26, 2024, at a price of $24.67 per share.
- This sale was made to cover withholding taxes and tax-related items associated with the vesting of restricted stock units.
- Schneyer also acquired 1,353 shares through the vesting of restricted stock units on February 23, 2024.
- Following these transactions, Schneyer directly owns 21,067 shares of Acadia Pharmaceuticals common stock and 1,353 restricted stock units.
- The restricted stock units vest in four equal annual installments beginning February 23, 2022.
Sentiment
Score: 6
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations. It doesn't indicate any significant positive or negative sentiment regarding the company's performance or future prospects.
Positives
- The vesting of restricted stock units indicates a form of compensation and alignment of the executive's interests with the company's performance.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies. This transaction appears to be a routine sale to cover tax obligations related to equity compensation.
Comparison to Industry Standards
- Executive compensation packages often include restricted stock units that vest over time.
- Sales of stock to cover tax obligations upon vesting are standard practice.
- The filing of Form 4 is a regulatory requirement for reporting insider transactions.
Stakeholder Impact
- The transaction is unlikely to have a significant impact on shareholders, as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| February 23, 2022 | Start date for annual vesting of restricted stock units in four equal installments. |
| February 23, 2024 | Acquisition of 1,353 shares through vesting of restricted stock units. |
| February 26, 2024 | Sale of 772 shares of common stock at $24.67 per share to cover tax obligations. |
| February 27, 2024 | Date of the Power of Attorney execution. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.